Video Experimental Relacionado
Updated: Sep 9, 2025
07:07
Measuring Glucose Uptake in Drosophila Models of TDP-43 Proteinopathy
Published on: August 3, 2021
2.9K
Dirigirse a los transportadores de glucosa en la enfermedad de Parkinson: un nuevo enfoque metabólico para la
Gursimran Singh1, Shazia Ansari1, Khadga Raj Aran2,3
1Department of Pharmacy Practice, ISF College of Pharmacy (An Autonomous College), Moga, Punjab, 142001, India.
Metabolic brain disease
|August 29, 2025
Resumen
Los transportadores de glucosa (GLUT) son cruciales para la energía cerebral. La disfunción GLUT está relacionada con la enfermedad de Parkinson (EP), pero la orientación de las GLUT y el uso de medicamentos antidiabéticos pueden ofrecer nuevas estrategias terapéuticas para la EP.
Área de la Ciencia:
- La neurociencia
- Trastornos del metabolismo
- Enfermedades neurodegenerativas
Sus antecedentes:
- El metabolismo de la glucosa es esencial para la función del sistema nervioso central (SNC), dependiendo de los transportadores de glucosa (GLUT).
- La deficiencia de GLUT y los problemas metabólicos están cada vez más relacionados con enfermedades neurodegenerativas como la enfermedad de Parkinson (EP).
- La EP incluye degeneración de neuronas dopaminérgicas, alteraciones motoras y no motoras y, a menudo, intolerancia a la glucosa y resistencia a la insulina.
Objetivo del estudio:
- Para revisar la conexión entre la disfunción GLUT y la EP.
- Para resaltar la desregulación GLUT como un objetivo terapéutico potencial para la EP.
- Explorar la reutilización de medicamentos antidiabéticos para el tratamiento de la enfermedad de Parkinson.
Principales métodos:
- Esto es una revisión narrativa.
- Sintetiza el conocimiento actual de los GLUT en la EP.
- Se discuten las estrategias terapéuticas dirigidas a los GLUT y a los medicamentos antidiabéticos.
Principales resultados:
- La expresión reducida de GLUT afecta la absorción neuronal de glucosa, la producción de ATP y aumenta el estrés oxidativo en la EP.
- La orientación de los GLUT puede ofrecer neuroprotección y reducir los déficits energéticos en la EP.
- Los medicamentos antidiabéticos son prometedores para mitigar los síntomas y la progresión de la enfermedad de Parkinson al mejorar la sensibilidad a la insulina y reducir la neuroinflamación.
Conclusiones:
- La disfunción GLUT es un factor significativo en la patogénesis de la EP.
- La orientación de los GLUT y la reutilización de los medicamentos antidiabéticos representan vías terapéuticas prometedoras para la EP.
- Superar desafíos como la especificidad de la isoforma GLUT y la penetración de la barrera hematoencefálica es clave para desarrollar terapias efectivas que modifiquen la enfermedad de Parkinson.
Palabras clave:
Resistencia a la insulinaNeurodegeneraciónEl estrés oxidativoAgregación de la α-sinucleínaMás Videos Relacionados
07:04Measuring Uptake of the Glucose Analog, 6-(N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino)-6-Deoxyglucose, in Intact Murine Neural Retina
Published on: March 14, 2025
446
05:38Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
18.2K
Videos de Conceptos Relacionados
01:24Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
01:32Secondary Active Transport
7.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.6K
01:15Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
01:27Glucose Transporters
24.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416